ORAGENICS INC
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
OGEN$0.35+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $11,403,766 | $864,840 |
| Prepaid expenses and other current assets | 1,301,778 | 607,670 |
| Total current assets | 12,705,544 | 1,472,510 |
| Total assets | $12,705,544 | $1,472,510 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $2,479,272 | $1,355,867 |
| Short-term notes payable, net of debt issuance costs | 394,836 | 328,528 |
| Total liabilities | 2,874,108 | 1,684,395 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, no par value; 50,000,000 shares authorized; 432,122 Series H and 7,488,692 Series F outstanding at September 30, 2025, and 0 Series H and 7,488,692 Series F outstanding at December 31, 2024. | - | - |
| Common stock, $0.001 par value; 350,000,000 shares authorized; 4,127,173 and 419,003 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively | 4,127 | 419 |
| Additional paid-in capital | 234,169,098 | 216,573,868 |
| Accumulated deficit | (224,341,789) | (216,786,172) |
| Total stockholders’ equity (deficit) | 9,831,436 | (211,885) |
| Total liabilities and stockholders’ equity (deficit) | $12,705,544 | $1,472,510 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.